Development and Use of Biomarkers in Oncology Drug Development

Toxicologic Pathology

Volumn 32, Issue SUPPL. 1, 2004, Pages 106-115

  Floyd, Eugenia ^a   McShane, Teresa M ^a  

^a PFIZER INC   (United States)

Author keywords

Anti cancer drug; Cancer; Genomics; Immunohistochemistry; Molecular imaging; MRI; PET; Proteomics; Surrogate endpoint

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CHEMICAL COMPOUND; LEAD DERIVATIVE; NEW DRUG; REAGENT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BIOASSAY; CLINICAL PROTOCOL; CLINICAL TRIAL; DECISION MAKING; DISEASE MARKER; DOSE CALCULATION; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FLOW CYTOMETRY; FUNCTIONAL IMAGING; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; IMAGING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LABORATORY AUTOMATION; MEASUREMENT; MEDICAL TECHNOLOGY; MOLECULAR IMAGING; NOMENCLATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; PATIENT SELECTION; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRECLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROCESS DESIGN; PRODUCTIVITY; PROTEOMICS; RADIOIMMUNOASSAY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARDIZATION; SURROGATE ENDPOINT;

ANIMALIA;

EID: 1842458410     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230490425021     Document Type: Article

References (101)

1. Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., Nicholson, R. I., and Baselga, J. (2002). Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20(1), 110-24.
2. Allen, L. F., Lenehan, P. F., Eiseman, I. A., Elliott, W. L., and Fry, D. W. (2002). Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 29 (3 Suppl 11), 11-21.
3. Ardekani, A. M., Petricoin, E. E, and Hackett, J. L. (2003). Molecular diagnostics: an FDA perspective. Expert Rev Mol Diagn 32(2), 129-40.
4. Arteaga, C. L. (2003). Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res 5(2), 96-100.
5. Baak, J. P. A. (2002). The framework of pathology: Good Laboratory Practice by quantitative and molecular methods. J Pathol 198, 277-83.
6. Barker, P. E. (2003). Cancer biomarker validation: standards and process. Roles for the National Institute of Standards and Technology (NIST). Ann NY Acad Sci 983, 142-50.
7. Bernard, P. S., and Wittwer, C. T. (2002). Real-time PCR technology for cancer diagnostics. Clin Chem 48(8), 1178-85.
8. Beshara, N., Fung, M. F. K., and Faught, W. (2002). The role of topotecan as a second-line therapy in patients with recurrent ovarian cancer. Eur J Gynaecol Oncol 23, 287-90.
9. Betensky, R. A., Louis, D. N., and Caimcross, J. G. (2002). Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20(10), 2495-9.
10. Biomarkers Defininitions Working Group (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69, 89-95.
11. Blasberg, R. (2003). Molecular imaging and cancer. Mol Cancer Ther 2, 333-43.
12. Brodie, A. (2003). Aromatose inhibitor development and hormone therapy: a perspective. Semin Oncol 30, 12-22.
13. Bruzzi, P. (2002). Objective response to treatment as a potential surrogate marker of survival in breast cancer. Ann NY Acad Sci 963, 144-7.
14. Butte, A. (2002). The use and analysis of microarray data. Nature Rev Drug Disc 1(12), 951-60.
15. Camp, R. L., Chung, G. G., and Rimm, D. L. (2002). Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature Med 8(11), 1323-7.
16. Capdeville, R., Buchdunger, E., Zimmermann, J., and Matter, A. (2002). Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug. Nature Rev Drug Discov 1(7), 493-502.
17. Chaurand, P., Schwartz, S. A., and Caprioli, R. (2002). Imaging mass spectrometry: a new tool to investigate the spatial organization of peptides and proteins in mammalian tissue sections. Curr Opin Chem Biol 6(5), 676-81.
18. Choyke, P. E., Dwyer, A. J., and Knopp, M. V. (2003). Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Res Imaging 17, 509-20.
19. Colburn, W. A. (2003). Biomarkers in drug discovery and development: From target identification through drug marketing. J Clin Pharmacol 43(4), 329-41.
20. Dancey, J., and Sausville, E. A. (2003). Issues and progress with protein kinase inhibitors for cancer treatment. Nature Rev Drug Disc 2, 296-313.
21. De Gruttola, V. G., Clax, P., DeMets, D. L., Downing, G. J., Ellenberg, S. S., Friedman, L., Gail, M. H., Prentice, R., Wittes, J., and Zeger, S. L. (2001). Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop. Control Clin Trials 22(5), 485-502.
22. Deptala, A., Bedner, E., and Darzynkiewicz, Z. (2001). Unique analytical capabilities of laser scanning cytometry that complement flow cytometry. Folia Histochem Cytobiol 39, 87-9.
23. DePrimo, S. E., Wong, L. M., Khatry, D. B., Nicholas, S. L., Manning, W. C., Smolich, B. D., O'Farrell, A. M., and Cherrington, J. M. (2003). Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMC Cancer 3, 3.
24. DiMasi, J. A. (2002). The value of improving the productivity of the drug development process. Pharmacoeconomics 20 (Suppl. 3), 1-10.
25. DiMasi, J. A., Hansen, R. W., and Grabowski, H. G. (2003). The price of innovation: new estimates of drug development costs. J Health Econ 22(2), 151-85.
26. Duffy, M. J. (2001). Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 38(3), 225-62.
27. Early Detection Research Network (2002). Translational research to identify early cancer and cancer risk, second report. (http://www3.cancer.gov/prevention/cbrg/edm/publications.html).
28. Eckelman, W.C. (2003). The use of PET and knockout mice in the drug discovery process. Drug Discov Today 8(9), 404-10.
29. Fauntleroy, M. (2001). Submission of images to the Center for Biologics Evaluation and Research in support of license applications for therapeutic agents. J Clin Pharmacol 41 (Suppl. S), 119S-21S.
30. Frank, R., and Hargreaves, R. (2003). Clinical biomarkers in drug discovery and development. Nature Rev Drug Discov 2(7), 566-80.
31. Haedicke, W., Popper, H. H., Buck, C. R., and Zatloukal, K. (2003). Automated evaluation and normalization of immunohistochemistry on tissue microarrays with a DNA microarray scanner. Biotechniques 35, 164-8.
32. Han, M., Gao, X., Su, J. Z., and Nie, S. (2001). Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules. Nature Biotechnol 19, 631-5.
33. Hariharan, R. (2003). The analysis of microarray data. Pharmacogenomics 4, 477-97.
34. Hirschfeld, S., and Pazdur, R. (2002). Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 42(2), 137-43.
35. Howell, K., Hopkins, N., and Mcloughlin, P. (2002). Combined confocal microscopy and stereology: a highly efficient and unbiased approach to quantitative structural measurement in tissues. Exp Physiol 87(6), 747-56.
36. 1H NMR spectra by pattern recognition. NMR Biomed 5, 59-64.
37. 31P magnetic resonance spectroscopy tumour spectra obtained in vivo. NMR Biomed 6, 237-41.
38. Huang, E., Ishida, S., Pittman, J., Dressman, H., Bild, A., Kloos, M., D'Amico, M., Pestell, R. G., West, M., and Nevins, J. R. (2003). Gene expression phenotypic models that predict the activity of oncogenic pathways. Nature Genet 34, 226-30.
39. Hutchinson, O. C., Collingridge, D. R., Barthel, H., Price, P. M., and Aboagye, E. O. (2003). Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography. J Curr Pharm Des 9, 917-29.
40. Hutchinson, O. C., Collingridge, D. R., Barthel, H., Price, P. M., and Aboagye, E. O. (2003). Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography. J Curr Pharm Des 9, 931-44.
41. Jackson, J. K., Gleave, M. E., Yago, V., Beraldi, E., Hunter, W. L., and Burt, H. M. (2000). The suppression of human prostate tumor growth in mice by the injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res 60(15), 4146-51.
42. Johnson, J. R., Williams, G., and Pazdur, R. (2003). End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21, 1404-11.
43. Jubb, A. M., Landon, T. H., Burwick, J., Pham, T. Q., Frantz, G. D., Cairns, B., Quirke, P., Peale, F. V., and Hillan, K. J. (2003). Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization. J Pathol 200(5), 577-88.
44. Kamentsky, L. A., Burger, D. E., Gershman, R. J., Kamentsky, L. D., and Luther, E. (1997). Slide-based laser scanning cytometry. Acta Cytol 41, 123-43.
45. Kavanaugh, C. J., Desai, K. V., Calvo, A., Brown, P. H., Couldrey, C., Lubet, R., and Green, J. E. (2002). Preclinical applications of transgenic mouse mammary cancer models. Transgenic Res 11, 617-33.
46. Kellar, K. L., and Iannone, M. A. (2002). Multiplexed microsphere-based flow cytometric assays. Expl Hematol 30(11), 1227-37.
47. Kennedy, T. (1997). Managing the drug discovery/development interface. Drug Discov Today 2(10), 436-44.
48. Keyes, K. A., Mann, L., Cox, K., Treadway, P., Iversen, P., Chen, Y. F., and Teicher, B. A. (2003). Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol 51(4), 321-7.
49. Kom, E. L., Arbuck, S. G., Pluda, J. M., Simon, R., Kaplan, R. S., and Christian, M. C. (2001). Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19(1), 265-72.
50. Lee, K. E., Sha, N., Dougherty, E. R., Vannucci, M., and Mallick, B. K. (2003). Gene selection: a Bayesian variable selection approach. Bioinformatics 19, 90-7.
51. Lesko, L. J., and Atkinson, A. J. (2001). Use of biomarkers and surrogate end-points in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41, 347-66.
52. Lim, Y. T., Kim, S., Nakayama, A., Stott, N. E., Bawendi, M. G., and Grangioni, J. V. (2003). Selection of quantum dot wavelengths for biomedical assays and imaging. Mol Imaging 2, 50-64.
53. Liotta, L. A., Espina, V., Mehta, A. I., Calvert, V., Rosenblatt, K., Geho, D., Munson, P. J., Young, L., Wulfkuhle, J., and Petricoin E. F. (2003). Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3(4), 317-25.
54. Lopez, A. M., Pegram, M. D., Slamon, D. J., and Landaw, E. M. (1999). A model-based approach for assessing in vivo combination therapy interactions. Proc Natl Acad Sci 96, 13023-8.
55. Ma, P. C., Blaszkowsky, L., Bharti, A., Ladanyi, A., Kraeft, S. K., Bruno, A., Skarin A. T., Chen, L. B., and Salgia, R. (2003). Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res 23(1A), 49-62.
56. MacGregor, P. F., and Squire, J. A. (2002). Application of microarrays to the analysis of gene expression in cancer. Clin Chem 48(8), 1170-7.
57. Malik, S. N., Siu, L. L., Rowinsky, E. K., deGraffenried, L., Hammond, L. A., Rizzo, J., Bacus, S., Brattain, M. G., Kreisberg, J. I., and Hidalgo, M. (2003). Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 9, 2478-86.
58. Mancuso, P., Calleri, A., Cassi, C., Gobbi, A., Capillo, M., Pruneri, G., Martinelli, G., and Bertolini, F. (2003). Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 522, 83-97.
59. Mandell, J. W. (2003). Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 163, 1687-98.
60. Mannix, D. G. (2000). Irinotecan - a case study for the transition from accelerated approval to traditional approval. Drug Inform J 34, 737-40.
61. Massoud, T. F., and Gamghir, S. S. (2003). Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17, 545-80.
62. Mauro, M. J., O'Dwyer, M., Heinrich, M. C., and Druker, B. J. (2002). STI571: A paradigm of new agents for cancer therapeutics. J Clin Oncol 20, 325-34.
63. McCaffrey, A., Kay, M. A., and Contag, C. H. (2003). Advancing molecular therapies through in vivo bioluminescent imaging. Mol Imaging 2, 75-86.
64. McDonald, D. M., and Choyke, P. L. (2003). Imaging of angiogenesis: from microscope to clinic. Nature Med 9, 713-25.
65. McIntosh, M. W., and Urban, N. (2003). A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics 4, 27-40.
66. Mendelsohn. J., and Baselga, J. (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21(14), 2787-99.
67. Mengel, M., von Wasielewski, R., Wiese, B., Rudiger, T., Muller-Hermelink, H., and Kreipe, H. (2002). Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 198, 292-9.
68. Nicholson, J. K., Connelly, J., Lindon, J. C., and Holmes, E. (2002). Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev Drug Discov 1(2), 153-61.
69. Nicholson, J. K., and Wilson, I. D. (2003). Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nature Rev Drug Discov 2(8), 668-76.
70. Nielsen, U. B., Cardon, M. H., Sinskey, A. J., MacBeath, G., and Sorger, P. K. (2003). Profiling receptor tyrosine kinase activation by using Ab arrays. Proc Natl Acad Sci USA 100, 9330-5.
71. Nishizuka, S., Chen, S., Gwadry, F. G., Alexander, J., Major, S. M., Scherf, U., Reinhold, W. C., Waltham, M., Charbonneau, L., Young, L., Bussey, K. J., Kim, S., Lababidi, S., Lee, J. K., Pittaluga, S., Scudiero, D. A., Sausville, E. A., Munson, P. J., Petricoin, E. F., Liotta, L. A., Hewitt, S. M., Raffeld, M., and Weinstein, J. N. (2003). Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic and tissue array profiling. Cancer Res 63, 5243-50.
72. Ochs, M. F., and Godwin, A. K. (2003). Microarrays in cancer: research and application. Biotechniques 34, S4-S15.
73. Parekattil, S. J., Fisher, H. A., and Kogan, B. A. (2003). Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractatn protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer. J Urol 169, 917-20.
74. Parton, M., Krajewski, S., Smith, I., Krajewska, M., Archer, C., Naito, M., Ahern, R., Reed, J., and Dowsett, M. (2002). Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res 8(7), 2100-8.
75. Paweletz, C. P., Charboneau, L., Bichsel, V. E., Simone, N. L., Chen, T., Gillespie, J. W., Emmert-Buck, M. R., Roth, M. J., Petricoin, E. F., and Liotta, L. A. (2001). Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981-9.
76. Pepe, M. S., Etzioni, R., Feng, Z. D., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., and Yasui, Y. (2001). Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93(14), 1054-61.
77. Petricoin, E. F., Hackett, J. L., Lesko, L. J., Puri, R. K., Gutman, S. I., Chumakov, K., Woodcock, J., Feigal, D. W., Zoon, K. C., and Sistare, F. D. (2002). Medical applications of microarray technologies: a regulatory science perspective. Nature Genet 32(Suppl. S), 474-9.
78. Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C., and Liotta, L. A. (2002). Clinical proteomics: Translating benchside promise into bedside reality. Nature Rev Drug Discov 1(9), 683-95.
79. Ringner, M., and Peterson, C. (2003). Microarray-based cancer diagnosis with artificial neural networks. Biotechniques 34, S30-5.
80. Rolan, P., Atkinson, A. J., and Lesko, L. J. (2003). Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther 73, 284-91.
81. Ross, B. D., Moffat, B. A., Lawrence, T. S., Mukherji, S. K., Gebarski, S. S., Quint, D. J., Johnson, T. D., Junck, L., Robertson, P. L., Muraszko, K. M., Dong, Q., Meyer, C. R., Bland, P. H., McConville, P., Geng, H., Rehemtulla, A., and Chenevert, T. L. (2003). Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2, 581-7.
82. Rudin, M., and Weissleder, R. (2003). Molecular imaging in drug discovery and development. Nature Rev Drug Discov 2, 123-31.
83. Sabri, S., Richelme, F., Pierres, A., Benoliel, A., and Bongrand, P. (1997). Interest of image processing in cell biology and immunology. J Immunol Meth 208, 1-27.
84. Sauter, G., Simor, R., and Hillan, K. (2003). Tissue microarrays in drug discovery. Nature Drug Disc 2, 962-72.
85. Sidransky, D. (2002). Emerging molecular markers of cancer. Nature Rev Cancer 2, 210-9.
86. Sindhi, R., Allaert, J., Gladding, D., Haaland, P., Koppelman, B., Dunne, J., and Sehgal, S. (2003). Modeling individual variation in biomarker response to combination immunosuppression with stimulated lymphocyte responses-potential clinical implications. J Immunol Meth 272(1-2), 257-72.
87. Shockcor, J. P., and Holmes, E. (2002). Metabonomic applications in toxicity screening and disease diagnosis. Curr Top Med Chem 2, 35-51.
88. Srinivas, P. R., Verma, M., Zhao, Y. M., and Srivastava, S. (2002). Proteomics for cancer biomarker discovery. Clin Chem 48(8), 1160-9.
89. Staal, F. J. T., van der Burg, M., Wessels, L. F. A., Barendregt, B. H., Baert, M. R. M., van den Burg, C. M. M., Van Huffel, C., Langerak, A. W., van der Velden, V. H. J., Reinders, M. J. T., and van Dongen, J. J. M. (2003). DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia 17(7), 1324-32.
90. Stadler, W. (2002). New trial designs to assess antitumor and antiproliferative agents in prostate cancer. Invest New Drugs 20, 201-8.
91. Sturgeon, C. (2002). Practice guidelines for tumor marker use in the clinic. Clin Chem 48(8), 1151-9.
92. Swanson, B. N. (2002) Delivery of high-quality biomarker assays. Dis Markers 18(2), 47-56.
93. Tarnok, A., and Gerstner, A. O. H. (2003). Clinical applications of laser scanning cytometry. Cytometry 50, 133-43.
94. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., and Gwyther, S. G. (2000). New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92, 205-16.
95. Ugrinska, A., Bombardieri, E., Stokkel, M. P. M., Crippa, F., and Pauwels, E. K. J. (2002). Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer. Q J Nucl Med 46(2), 88-104.
96. van der Velden, V. H. J., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J., and van Dongen, J. J. M. (2003). Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17(6), 1013-34.
97. Veltri, R. W., Miller, M. C., and An, G. (2001). Standardization, analytical validation, and quality control of intermediate endpoint biomarkers. Urology 57(4A Suppl. S), 164-70.
98. Welsh, J. B., Sapinoso, L. M., Kern, S. G., Brown, D. A., Liu, T., Bauskin, A. R., Ward, R. L., Hawkins, N. J., Quinn, D. I., Russell, P. J., Sutherland, R. L., Breit, S. N., Moskaluk, C. A., Frierson, H. F., and Hampton, G. M. (2003). Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 100, 3410-5.
99. Wulfkuhle, J. D., Liotta, L. A., and Petricoin, E. F. (2003). Proteomic applications for the early detection of cancer. Nature Rev Cancer 3(4), 267-75.
100. Yamori, T. (2003). Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharmacol 52 (Suppl. 1), S74-9.
101. Zehentner, B. K., Dillon, D. C., Jiang, Y. Q., Xu, J. C., Bennington, A., Molesh, D. A., Zhang, X. Q., Reed, S. G., Persing, D. H., and Houghton, R. L. (2002). Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem 48(8), 1225-31.